Advertisement
Australia markets closed
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • AUD/USD

    0.6545
    +0.0022 (+0.34%)
     
  • OIL

    84.42
    +0.85 (+1.02%)
     
  • GOLD

    2,359.90
    +17.40 (+0.74%)
     
  • Bitcoin AUD

    98,361.64
    +886.07 (+0.91%)
     
  • CMC Crypto 200

    1,388.39
    -8.15 (-0.59%)
     
  • AUD/EUR

    0.6102
    +0.0029 (+0.47%)
     
  • AUD/NZD

    1.0990
    +0.0033 (+0.30%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,118.49
    +39.63 (+0.49%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    18,050.34
    +133.06 (+0.74%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Can Pfizer and GlaxoSmithKline Beat Johnson & Johnson's RSV Vaccine?

Johnson & Johnson (NYSE: JNJ) recently announced positive results from a phase 2 study of its RSV vaccine candidate. In this Motley Fool Live video recorded on Oct. 6, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J set a high bar for Pfizer (NYSE: PFE) and GlaxoSmithKline (NYSE: GSK) to top.